Last checked at 
LONDON, Feb 3 (Reuters) - Data that shows 92% efficacy of
Russia's Sputnik V vaccine is welcome, and more studies should
be done to show if giving doses of different vaccines can be
effective, AstraZeneca's research chief said on Wednesday.
Clinical trials that combine doses of AstraZeneca's shot and
Sputnik V are underway, using a technique known as heterologous
boosting.
"I think any data or any vaccine that shows high levels of
efficacy I think is encouraging because we need all of these
vaccines to work," Mene Pangalos told reporters when asked about
the Sputnik V results.
"In terms of the heterologous boosting experiment that we're
doing in the clinic, using our vaccine and the Sputnik vaccine,
it's something that we need to be doing more of, because
ultimately we want to understand how interchangeable these
vaccines are," he said, adding he hoped for data on immune
responses from the trials in the coming months.
(Reporting by Alistair Smout)
